American journal of kidney diseases : the official journal of the National Kidney Foundation
-
Randomized Controlled Trial
A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.
Previous small uncontrolled studies suggested that fludrocortisone may significantly decrease serum potassium concentrations in hemodialysis patients, possibly through enhancement of colonic potassium secretion. The aim of this study is to evaluate the effect of oral fludrocortisone on serum potassium concentrations in hyperkalemic hemodialysis patients in an open-label randomized controlled trial. ⋯ Administering fludrocortisone to hyperkalemic hemodialysis patients is safe and well tolerated, but does not achieve clinically important decreases in serum potassium levels.